Related Experiment Video
Updated: Oct 14, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
[Cryptogenic stroke management : where are we ?]
P Aubry1, F Hamidouche2, A Alqudwa2
1Service de cardiologie, Centre Hospitalier de Gonesse, 95500 Gonesse; Département de cardiologie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Bichat-Claude-Bernard, 75018 Paris.
Embolic stroke of undetermined source remains a complex diagnosis. Identifying the exact cause, like atherosclerosis over covert atrial fibrillation, requires further research and cardiologist involvement for better patient treatment.
Area of Science:
- Neurology
- Cardiology
- Stroke Medicine
Background:
- Cryptogenic stroke is an outdated term for ischemic stroke without a clear cause.
- Embolic stroke of undetermined source (ESUS) was introduced for non-lacunar strokes with likely thromboembolic mechanisms.
- The ESUS subgroup is heterogeneous, with multiple potential embolic causes.
Purpose of the Study:
- To explore the heterogeneity of ESUS.
- To contrast the prevalence of covert atrial fibrillation versus intracranial and extracranial atherosclerosis in ESUS.
- To emphasize the role of cardiologists in diagnosing ESUS.
Main Methods:
- Review of existing literature on cryptogenic stroke and ESUS.
- Analysis of potential embolic causes, including atrial fibrillation and atherosclerosis.
- Discussion of diagnostic approaches and the neurologist-cardiologist collaboration.
Main Results:
- Covert atrial fibrillation is less frequently the cause of ESUS than initially anticipated.
- Intracranial and extracranial atherosclerosis are more significant contributors to ESUS.
- The heterogeneity of ESUS necessitates a broad diagnostic approach.
Conclusions:
- ESUS is a complex condition with diverse underlying etiologies.
- Cardiologists play a crucial role in the etiological workup of ischemic stroke.
- Further research is needed to personalize treatments for ESUS patients.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

